Contact
searchSearch
HMP Global
Presentations

Metastatic Disease: What I Need to Know

Symposium on Clinical Interventional Oncology 2021

Stay in the Know

Vascular Disease Management Newsletter

News

Stroke
Upfront Diagnostics Launches LVOne Rapid Stroke Blood Test Following Receiving UKCA; First Deployment Begins With London Ambulance Service
05/05/2026
May 5, 2026 – Cambridge, UK – Upfront Diagnostics today announced the commercial launch of LVOne, a rapid blood test designed to help identify large vessel occlusion (LVO) strokes in the pre-hospital setting. The test has received UKCA...
May 5, 2026 – Cambridge, UK – Upfront Diagnostics today announced the commercial launch of LVOne, a rapid blood test designed to help identify large vessel occlusion (LVO) strokes in the pre-hospital setting. The test has received UKCA...
May 5, 2026 – Cambridge, UK –...
05/05/2026
Vascular Disease Management
Pulmonary embolism
Thrombolex Announces Enrollment of 100th Patient in RAPID-PE Clinical Study
05/01/2026
Landmark Milestone Reached in Single-Arm Study Evaluating the BASHIR® Endovascular System for Pulmonary Embolism Treatment New Britain, PA, April 30, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally...
Landmark Milestone Reached in Single-Arm Study Evaluating the BASHIR® Endovascular System for Pulmonary Embolism Treatment New Britain, PA, April 30, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally...
Landmark Milestone Reached in...
05/01/2026
Vascular Disease Management
Drug-Eluting Balloons
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan 
04/30/2026
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.(2)
The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through three years.(2)
The SELUTION SFA Japan clinical...
04/30/2026
Cath Lab Digest
Below-Ankle Intervention
Saving Limbs Where Others Stop: Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle
04/29/2026
Serration Remodeling Therapy (SRT) is a novel approach to optimizing luminal gain by gently remodeling the internal elastic lamina through creating a line of weakness to reduce recoil and support durable outcomes.
Serration Remodeling Therapy (SRT) is a novel approach to optimizing luminal gain by gently remodeling the internal elastic lamina through creating a line of weakness to reduce recoil and support durable outcomes.
Serration Remodeling Therapy...
04/29/2026
Vascular Disease Management
Sirolimus-coated Balloons
Concept Medical Announces Preliminary 3-Year Sirona Data at Charing Cross Symposium 2026
04/28/2026
Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrate Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease London, 21 April 2026: Concept Medical Inc., today announced the presentation of preliminary...
Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrate Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease London, 21 April 2026: Concept Medical Inc., today announced the presentation of preliminary...
Preliminary 3-Year SIRONA Data...
04/28/2026
Vascular Disease Management
Bioresorbable Scaffolds
REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Critical Limb-Threatening Ischemia Patients
04/23/2026
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.
The MOTIV BTK trial met both its...
04/23/2026
Cath Lab Digest
BTK Intervention
Abbott Unveils Post-Approval Study Data Demonstrating Potential of Esprit BTK to Treat Significantly Sicker Patients with CLTI and Complex Lesions
04/21/2026
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the Esprit™ BTK Post-Approval Study (PAS) presented at the Charing Cross Symposium in London, UK, revealed promising 30-day results that...
Initial data from the...
04/21/2026
Cath Lab Digest
Chronic Venous Disease
InVera Medical Reports 12-Month Results From Pilot Trial of InVera Infusion Device Showing Vein Closure in 90% of Patients, Statistically Significant Quality of Life Improvements, and Excellent Safety
04/21/2026
Novel Non-Thermal Procedure for Chronic Venous Disease Designed to Effectively Eliminate Need for Painful Injections Required for Thermal Ablation
Novel Non-Thermal Procedure for Chronic Venous Disease Designed to Effectively Eliminate Need for Painful Injections Required for Thermal Ablation
Novel Non-Thermal Procedure for...
04/21/2026
Vascular Disease Management
Femoropopliteal Disease
Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
04/21/2026
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif. — Efemoral Medical announced that at the Charing Cross Symposium in London, UK, EFEMORAL I Principal Investigator Prof. Andrew Holden of Auckland, NZ, presented the long-term results of the first 40 patients...
LOS ALTOS, Calif....
04/21/2026
Cath Lab Digest
Arteriovenous Fistula
Medtronic Reports Strong 12-Month Real-World Outcomes for IN.PACT™ AV Drug-Coated Balloon†
04/16/2026
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1 Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population1 Medtronic, a global leader in healthcare technology, today announced...
Post-approval study’s primary...
04/16/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use